Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alphamab Oncology ( (HK:9966) ) has provided an announcement.
Alphamab Oncology reported 2025 revenue of RMB566.2 million, down from RMB640.1 million a year earlier, and swung to a net loss of RMB113.9 million from a prior profit, as research and development spending rose sharply to RMB572.2 million. The company’s net assets slipped to RMB1.71 billion, reflecting continued heavy investment in its pipeline despite weaker top-line performance.
Operationally, Alphamab advanced several key clinical programs, including publishing positive phase II data on KN026 in HER2-positive metastatic breast cancer and dosing the first patient in a China phase I/II trial of JSKN033 for advanced metastatic tumors. The group also secured Chinese regulatory approval to launch phase III trials of JSKN003 in HER2-positive breast cancer and platinum-resistant ovarian cancer, milestones that could strengthen its oncology portfolio and competitive standing if later-stage data prove successful and support eventual commercialization.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a Hong Kong-listed biopharmaceutical company focused on developing innovative oncology therapies, particularly antibody and antibody–drug conjugate treatments for solid tumors. The group concentrates on HER2-positive cancers and other advanced metastatic malignancies, with a strong emphasis on clinical-stage R&D in the Chinese market and broader global oncology landscape.
Average Trading Volume: 1,405,997
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.95B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.